{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:29:24Z","timestamp":1793305764421,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025294","name":"Research Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Taighde \u00c9ireann - Research Ireland","doi-asserted-by":"publisher","award":["22\/PATH-S\/10804"],"award-info":[{"award-number":["22\/PATH-S\/10804"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.mib.2026.102794","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:00:27Z","timestamp":1784271627000},"page":"102794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Antisense oligonucleotides: design, implementation and future perspectives in microbiology"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7583-7444","authenticated-orcid":false,"given":"Jessica B","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5349-3986","authenticated-orcid":false,"given":"Glen","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3636-700X","authenticated-orcid":false,"given":"Merve S","family":"Zeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2026.102794_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/bmj.304.6834.1103","article-title":"Gene regulation","volume":"304","author":"Latchman","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.mib.2026.102794_bib2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41573-025-01237-x","article-title":"RNA chemistry and therapeutics","volume":"24","author":"Wang","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.mib.2026.102794_sbref3","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuaf059","article-title":"Developing antisense oligomer biotics \"asobiotics\" as precision antibacterials: designs, strategies, and considerations for future success","volume":"50","author":"Moustafa","year":"2026","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.mib.2026.102794_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00253-017-8671-0","article-title":"Advances in therapeutic bacterial antisense biotechnology","volume":"102","author":"Hegarty","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.mib.2026.102794_bib5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: one gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.mib.2026.102794_bib6","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s13311-023-01423-y","article-title":"Evolving therapeutic options for the treatment of Duchenne muscular dystrophy","volume":"20","author":"D'Ambrosio","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.mib.2026.102794_bib7","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050707","article-title":"Impact of distinct dystrophin gene mutations on behavioral phenotypes of Duchenne muscular dystrophy","volume":"17","author":"Saoudi","year":"2024","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.mib.2026.102794_bib8","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3390\/cells13110972","article-title":"A novel CRISPR-Cas9 strategy to target DYSTROPHIN mutations downstream of exon 44 in patient-specific DMD iPSCs","volume":"13","author":"Dhoke","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.mib.2026.102794_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.mib.2026.102794_bib10","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Grana","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mib.2026.102794_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41579-023-00993-0","article-title":"Alternative therapeutic strategies to treat antibiotic-resistant pathogens","volume":"22","author":"Macnair","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2026.102794_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics","volume":"22","author":"Miller","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2026.102794_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012270","article-title":"How can we escape the ESKAPEs: antimicrobial resistance mechanisms and what lies ahead?","volume":"20","author":"Kelly","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2026.102794_bib14","unstructured":"O'Neill J: The review on antimicrobial resistance. Final Report; 2016. \u3008http:\/\/amr-review.org\/Publications\u3009."},{"key":"10.1016\/j.mib.2026.102794_bib15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","author":"Collaborators","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2026.102794_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-neuro-070918-050501","article-title":"Antisense oligonucleotide therapies for neurodegenerative diseases","volume":"42","author":"Bennett","year":"2019","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.mib.2026.102794_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ajhg.2019.05.008","article-title":"NCALD antisense oligonucleotide therapy in addition to nusinersen further ameliorates spinal muscular atrophy in mice","volume":"105","author":"Torres-Benito","year":"2019","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.mib.2026.102794_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2026.102794_sbref18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41586-025-09499-6","article-title":"Programmable antisense oligomers for phage functional genomics","volume":"646","author":"Gerovac","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.mib.2026.102794_sbref19","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03983-24","article-title":"RNA toehold switch-based reporter assay to assess bacterial uptake of antisense oligomers","volume":"16","author":"Sarkar","year":"2025","journal-title":"mBio"},{"key":"10.1016\/j.mib.2026.102794_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1261\/rna.079263.122","article-title":"Design and off-target prediction for antisense oligomers targeting bacterial mRNAs with the MASON web server","volume":"29","author":"Jung","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.mib.2026.102794_sbref21","doi-asserted-by":"crossref","first-page":"W39","DOI":"10.1093\/nar\/gkaf392","article-title":"ASOptimizer: optimizing chemical diversity of antisense oligonucleotides through deep learning","volume":"53","author":"Kang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.mib.2026.102794_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102351","article-title":"Mechanistic insights into ASO-RNA complexation: advancing antisense oligonucleotide design strategies","volume":"35","author":"H\u00f6rberg","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.mib.2026.102794_bib24","article-title":"Structural dynamics of therapeutic nucleic acids with phosphorothioate backbone modifications","volume":"6","author":"Carlesso","year":"2024","journal-title":"NAR Genom Bioinforma"},{"key":"10.1016\/j.mib.2026.102794_bib25","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1002\/cmdc.202100388","article-title":"Efficient synthesis of 2\u2019-O-methoxyethyl oligonucleotide-cationic peptide conjugates","volume":"16","author":"Halloy","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.mib.2026.102794_sbref25","doi-asserted-by":"crossref","first-page":"ugag009","DOI":"10.1093\/narmme\/ugag009","article-title":"The impact of chemical modifications of antisense oligonucleotides on CTX-M-15 beta-lactamase target affinity and expression of ceftriaxone-resistant Escherichia coli","volume":"3","author":"Barry","year":"2026","journal-title":"NAR Mol Med"},{"key":"10.1016\/j.mib.2026.102794_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/antibiotics10040379","article-title":"Can vitamin B12 assist the internalization of antisense LNA oligonucleotides into bacteria?","volume":"10","author":"Pereira","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.mib.2026.102794_bib28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/nar\/gkt1090","article-title":"Redox-active quinones induces genome-wide DNA methylation changes by an iron-mediated and Tet-dependent mechanism","volume":"42","author":"Zhao","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.mib.2026.102794_bib29","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1093\/nar\/gkg409","article-title":"Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2\u2032-O-methyl RNA, phosphorothioates and small interfering RNA","volume":"31","author":"Grunweller","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.mib.2026.102794_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1660799","article-title":"Antisense phosphorodiamidate morpholino oligomers retain activity in Burkholderia cepacia complex biofilm","volume":"16","author":"Mendez","year":"2025","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mib.2026.102794_bib31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1457496920913666","article-title":"A single parathyroid hormone measurement two hours after a thyroidectomy reliably predicts permanent hypoparathyroidism","volume":"110","author":"Palmhag","year":"2021","journal-title":"Scand J Surg"},{"key":"10.1016\/j.mib.2026.102794_bib32","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1093\/nar\/gkaa126","article-title":"Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model","volume":"48","author":"Sheng","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.mib.2026.102794_bib33","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dky058","article-title":"Morpholino oligomers tested in vitro, in biofilm and in vivo against multidrug-resistant Klebsiella pneumoniae","volume":"73","author":"Geller","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2026.102794_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01938-16","article-title":"Inhibition of Pseudomonas aeruginosa by peptide-conjugated phosphorodiamidate morpholino oligomers","volume":"61","author":"Howard","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2026.102794_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01315-17","article-title":"MCR-1 Inhibition with peptide-conjugated phosphorodiamidate morpholino oligomers restores sensitivity to polymyxin in Escherichia coli","volume":"8","author":"Daly","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.mib.2026.102794_sbref35","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02622-24","article-title":"An antisense peptide-conjugated peptide nucleic acid (PPNA) for peptidoglycan recycling inhibition reduces AmpC hyperproduction and beta-lactam resistance in Pseudomonas aeruginosa","volume":"13","author":"Escobar-Salom","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.mib.2026.102794_sbref36","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1021\/acs.bioconjchem.5c00215","article-title":"Aminoglycoside-peptide nucleic acid (PNA) conjugates against Gram-negative bacteria","volume":"36","author":"Siekierska","year":"2025","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.mib.2026.102794_sbref37","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102762","article-title":"Antibacterial activities of novel peptide nucleic acids targeting Salmonella penicillin-binding proteins","volume":"36","author":"El-Fateh","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.mib.2026.102794_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.843163","article-title":"An efficient approach for the design and synthesis of antimicrobial peptide-peptide nucleic acid conjugates","volume":"10","author":"Patil","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.mib.2026.102794_bib40","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ymthe.2020.10.017","article-title":"Efficient gene suppression by DNA\/DNA double-stranded oligonucleotide in vivo","volume":"29","author":"Asami","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.mib.2026.102794_bib41","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.2147\/IJN.S109600","article-title":"Bolaamphiphile-based nanocomplex delivery of phosphorothioate gapmer antisense oligonucleotides as a treatment for Clostridium difficile","volume":"11","author":"Hegarty","year":"2016","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.mib.2026.102794_bib42","doi-asserted-by":"crossref","first-page":"16240","DOI":"10.1021\/jacs.0c04335","article-title":"Synthesis and characterization of thiophosphoramidate morpholino oligonucleotides and chimeras","volume":"142","author":"Langner","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.mib.2026.102794_bib43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsinfecdis.5c00779","article-title":"Rational design of chimeric antisense oligonucleotides that target FMN riboswitch mRNAs and inhibit the growth of methicillin-resistant Staphylococcus aureus","volume":"12","author":"Dyakova","year":"2026","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2026.102794_bib44","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1021\/acsinfecdis.1c00601","article-title":"Liposome delivery of nucleic acids in bacteria: toward in vivo labeling of human microbiota","volume":"8","author":"Moreira","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2026.102794_sbref44","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202402405","article-title":"Catechol-siderophore mimics convey nucleic acid therapeutics into bacteria","volume":"63","author":"Pals","year":"2024","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.mib.2026.102794_bib46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1021\/acsomega.8b03139","article-title":"Inhibition of Escherichia coli growth by vitamin B12\u2013peptide nucleic acid conjugates","volume":"4","author":"R\u00f3wnicki","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.mib.2026.102794_bib47","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1039\/D4CS00238E","article-title":"Chemical strategies for antisense antibiotics","volume":"53","author":"Pals","year":"2024","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.mib.2026.102794_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s42003-021-01726-w","article-title":"Identification of efficient prokaryotic cell-penetrating peptides with applications in bacterial biotechnology","volume":"4","author":"Lee","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.mib.2026.102794_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/ddr.430350105","article-title":"Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers","volume":"35","author":"Miller","year":"2008","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.mib.2026.102794_bib50","doi-asserted-by":"crossref","unstructured":"Ramu H et al: Facile siderophore assembly enables bacterial delivery of nucleic acid therapeutics. ChemRxiv. DOI: 10.26434\/chemrxiv.10001672\/v1.","DOI":"10.26434\/chemrxiv.10001672\/v1"},{"key":"10.1016\/j.mib.2026.102794_bib51","doi-asserted-by":"crossref","first-page":"15951","DOI":"10.2147\/IJN.S576272","article-title":"The role of bacterial siderophores in infection therapy: from anti-infective mechanisms to therapeutic advances","volume":"20","author":"Xiao","year":"2025","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.mib.2026.102794_bib52","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2026.102794_bib53","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.mib.2026.102794_bib54","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.3390\/molecules26082119","article-title":"A versatile solid-phase approach to the synthesis of oligonucleotide conjugates with biodegradable hydrazone linker","volume":"26","author":"Meschaninova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.mib.2026.102794_bib55","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1021\/jacs.0c12043","article-title":"Glucagon like peptide 1 receptor agonists for targeted delivery of antisense oligonucleotides to pancreatic beta cell","volume":"143","author":"Knerr","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.mib.2026.102794_bib56","doi-asserted-by":"crossref","first-page":"11031","DOI":"10.3390\/cimb46100655","article-title":"Peptide\u2013oligonucleotide conjugation: chemistry and therapeutic applications","volume":"46","author":"Malinowska","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.mib.2026.102794_bib57","doi-asserted-by":"crossref","first-page":"7523","DOI":"10.1002\/anie.200802651","article-title":"Hydrolytic stability of hydrazones and oximes","volume":"47","author":"Kalia","year":"2008","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.mib.2026.102794_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: a comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.mib.2026.102794_bib59","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1021\/acssynbio.1c00443","article-title":"Targeting glmS ribozyme with chimeric antisense oligonucleotides for antibacterial drug development","volume":"10","author":"Traykovska","year":"2021","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.mib.2026.102794_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1021\/acsinfecdis.5c00600","article-title":"Antisense oligomer targeting the antibiotic resistance gene ermC augments erythromycin, azithromycin, and virginiamycin sensitivity in Staphylococcus aureus","volume":"12","author":"Jire","year":"2026","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2026.102794_bib61","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1042\/BCJ20253458","article-title":"Modulating backbone flexibility in hydroxamate siderophores for improved iron chelation and peptide nucleic acid delivery into bacteria","volume":"483","author":"Tsylents","year":"2026","journal-title":"Biochem J"},{"key":"10.1016\/j.mib.2026.102794_bib62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17460441.2026.2652440","article-title":"The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery","volume":"21","author":"Ruchi","year":"2026","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.mib.2026.102794_bib63","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41586-024-08462-1","article-title":"Rapid and scalable personalized ASO screening in patient-derived organoids","volume":"638","author":"Means","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.mib.2026.102794_bib64","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/s41467-026-69980-2","article-title":"Dysregulation of the DNA damage response by phosphorothioate antisense oligonucleotides","volume":"17","author":"Hjelmgren","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2026.102794_bib65","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1021\/acsinfecdis.9b00123","article-title":"AcrAB\u2013TolC inhibition by peptide-conjugated phosphorodiamidate morpholino oligomers restores antibiotic activity in vitro and in vivo","volume":"5","author":"Sturge","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2026.102794_bib66","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41429-018-0056-9","article-title":"Cationic amphiphilic bolaamphiphile-based delivery of antisense oligonucleotides provides a potentially microbiome sparing treatment for C. difficile","volume":"71","author":"Sharma","year":"2018","journal-title":"J Antibiot"},{"key":"10.1016\/j.mib.2026.102794_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1331021","article-title":"Iron uptake pathway of Escherichia coli as an entry route for peptide nucleic acids conjugated with a siderophore mimic","volume":"15","author":"Tsylents","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mib.2026.102794_bib68","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1039\/C8CC05064C","article-title":"Vitamin B12 transports modified RNA into E. coli and S. Typhimurium cells.","volume":"55","author":"Giedyk","year":"2019","journal-title":"Chem Commun"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527426000883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527426000883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:22:36Z","timestamp":1788294156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527426000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":68,"alternative-id":["S1369527426000883"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2026.102794","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense oligonucleotides: design, implementation and future perspectives in microbiology","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2026.102794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102794"}}